Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1999;30:2391-2399

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, W.-J.
Right arrow Articles by Armstead, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, W.-J.
Right arrow Articles by Armstead, W. M.

(Stroke. 1999;30:2391-2399.)
© 1999 American Heart Association, Inc.


Original Contributions

Blockade of Central Angiotensin AT1 Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in Rats

Wen-Jie Dai, MD; Alexandra Funk; Thomas Herdegen, MD; Thomas Unger, MD Juraj Culman, MD

From the Institute of Pharmacology, Christian-Albrechts-University of Kiel, Germany.

Correspondence to Juraj Culman MD, Institute of Pharmacology, Christian-Albrechts- University of Kiel, Hospitalstrasse 4, 24105 Kiel, Germany. E-mail juraj.culman{at}pharmakologie.uni-kiel.de

Background and Purpose—Angiotensin-converting enzyme inhibitors have been shown to protect against stroke in hypertensive rats and to improve neurological outcome after cerebral ischemia in normotensive rats. The present study was designated to test the hypothesis that blockade of brain AT1 receptors improves the recovery from focal cerebral ischemia and reduces expression of AP-1 transcription factors c-Fos and c-Jun, which have been associated with programmed cell death and neurodegeneration.

Methods—Experiments were carried out in normotensive male Wistar rats. Focal cerebral ischemia was induced by middle cerebral artery occlusion lasting for 90 minutes and followed by reperfusion. The selective AT1 receptor antagonist irbesartan was infused intracerebroventricularly over a 5-day period before the induction of ischemia at a dose that inhibited brain but not vascular AT1 receptors. Twenty-four hours after ischemia, neurological outcome was evaluated and expression of c-Fos and c-Jun proteins in the brain was studied immunocytochemically.

Results—Focal brain ischemia resulted in a strong induction of c-Fos and c-Jun proteins in the cortex, which positively correlated with the degree of neurological deficits. Treatment of rats with irbesartan significantly improved neurological outcome of focal cerebral ischemia when compared with the vehicle-treated group and markedly reduced the expression of c-Fos and c-Jun proteins in the cortex on the ligated side of the brain. Irbesartan pretreatment completely abolished the ischemia-induced c-Fos expression in the hippocampus.

Conclusions—The present study shows a relationship between c-Fos and c-Jun expression and neurological outcome after focal brain ischemia. Our data indicate that long-term blockade of central AT1 receptors improves the recovery from brain ischemia and reduces the expression of c-Fos and c-Jun proteins in the brain. Pretreatment with an AT1 receptor antagonist has beneficial effects after cerebral ischemia.

Editorial Comment

William M. Armstead, PhD, Guest Editor

Department of Anesthesia, University of Pennsylvania, Philadelphia, Pennsylvania




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al.
Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Ishikawa, E. Sekizuka, N. Yamaguchi, H. Nakadate, S. Terao, D. N. Granger, and H. Minamitani
Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-endothelial cell interactions in the cerebral microvasculature
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2306 - H2315.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. Deplanque, I. Masse, C. Lefebvre, C. Libersa, D. Leys, and R. Bordet
Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity
Neurology, October 24, 2006; 67(8): 1403 - 1410.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman
Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats
FASEB J, June 1, 2006; 20(8): 1162 - 1175.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. H. Munzenmaier and A. S. Greene
Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H512 - H516.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Forder, D. H. Munzenmaier, and A. S. Greene
Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat
Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1989 - H1996.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. Kusaka, G. Kusaka, C. Zhou, M. Ishikawa, A. Nanda, D. N. Granger, J. H. Zhang, and J. Tang
Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2442 - H2451.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Fournier, F. H. Messerli, J. M. Achard, and L. Fernandez
Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials
J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1343 - 1347.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
T. WALTHER, L. OLAH, C. HARMS, B. MAUL, M. BADER, H. HORTNAGL, H.-P. SCHULTHEISS, and G. MIES
Ischemic injury in experimental stroke depends on angiotensin II
FASEB J, February 1, 2002; 16(2): 169 - 176.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Gohlke, S. Weiss, A. Jansen, W. Wienen, J. Stangier, W. Rascher, J. Culman, and T. Unger
AT1 Receptor Antagonist Telmisartan Administered Peripherally Inhibits Central Responses to Angiotensin II in Conscious Rats
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 62 - 70.
[Abstract] [Full Text]


Home page
Nephrol Dial TransplantHome page
A. Fournier, H. Mazouz, and J. M. Achard
STOPPING at the CAPPP of good HOPE
Nephrol. Dial. Transplant., January 1, 2001; 16(1): 185 - 187.
[Full Text]


Home page
StrokeHome page
Y. Nishimura, T. Ito, J. M. Saavedra, and K. Sandberg
Angiotensin II AT1 Blockade Normalizes Cerebrovascular Autoregulation and Reduces Cerebral Ischemia in Spontaneously Hypertensive Rats Editorial Comment
Stroke, October 1, 2000; 31(10): 2478 - 2486.
[Abstract] [Full Text] [PDF]